Moderna and the Japanese Government Reach an Agreement to Supply Japan with Additional 70 Million Doses of Moderna’s COVID-19 Booster Vaccine
Moderna has reached an agreement with the Ministry of Health, Labor, and Welfare of Japan (MHLW) to supply Japan with an additional 70 million doses of its COVID-19 Booster Vaccine.
Moderna announced on March 16, 2022 that it has reached an agreement with the Ministry of Health, Labor, and Welfare of Japan (MHLW) to supply Japan with an additional 70 million doses of its COVID-19 booster vaccine or an updated booster vaccine candidate for anticipated delivery in the second half of 2022.
Currently there are 93 million doses of Moderna’s COVID-19 vaccine contracted for supply to Japan. The agreement brings the potential total to 163 million doses, contingent to the Ministry securing a budget for the additional supply.
The MHLW has granted authorization for special approval to Moderna’s COVID-19 vaccine for people aged 18 years and older. The vaccine is delivered in two doses 28 days apart, with a booster dose available to be administered after at least six months of the second dose.
Source: Moderna
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Pfizer Obtains Exclusive Rights to 3SBio’s Bispecific Antibody Targeting PD-1 and VEGF
August 5th 2025The licensing agreement between the two companies gives Pfizer the rights to develop, manufacture, and commercialize 3SBio’s bispecific antibody, SSGJ-707, which is in clinical trials for the treatment of a variety of cancers.
